Mesoblast Shares Climb as Celgene Invests $45 Million

The Summit, New Jersey-based Celgene will pay A$3.82 each for 15.3 million shares, Mesoblast said in a statement today. That's 19 percent higher than Mesoblast's closing price of A$3.21 on April 10. Celgene, the maker of the cancer drug Revlimid, will gain six-month right of first refusal on Mesoblast's stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological ailments.

http://washpost.bloomberg.com/Story?docId=1376-NMPZ4J6JIJUO01-3J2SGGGDVEQLU8GVULRHAHF8JE